Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose, Two-Sequence, Crossover Study in Healthy Korean Male Volunteers
Authors:
- SoJeong YiSYSoJeong Yi
- Tae-Eun KimTKTae-Eun Kim
- JaeWoo KimJKJaeWoo Kim
- Sang-Goo ShinSSSang-Goo Shin
- In-Jin JangIJIn-Jin Jang
- Kyung-Sang YuKYKyung-Sang Yu
- 1 December 2011
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 33 (12) , 2029-2037
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Treatment of rheumatoid arthritis with tumour necrosis factor inhibitorsBritish Journal of Pharmacology, 2011
- Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeuticsImmunological Reviews, 2008
- The Comparability of Etanercept Pharmacokinetics in Healthy Japanese and American SubjectsThe Journal of Clinical Pharmacology, 2006
- Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion ProteinThe Journal of Clinical Pharmacology, 2005
- Absence of a Pharmacokinetic Interaction between Etanercept and WarfarinThe Journal of Clinical Pharmacology, 2004
- Uncoupling of inflammatory and destructive mechanisms in arthritisSeminars in Arthritis and Rheumatism, 2001
- The Pharmacokinetics of Etanercept in Healthy VolunteersAnnals of Pharmacotherapy, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope.Circulation, 1990
- Tumour necrosis factor in synovial exudates.Annals of the Rheumatic Diseases, 1988